AIM: The aim of the study was to investigate the potential role of BMP6 in TGF-beta1-mediated changes in HK-2 cells. METHODS: BMP6 was purified via heparin affinity and reverse phase liquid chromatography. The purity, specificity, and bioactivity of BMP6 were determined by SDS-PAGE, Western blot assays, and the induction of alkaline phosphatase (ALP) activity, respectively. Cell proliferation, morphology, and expression levels of alpha-SMA and E-cadherin were assessed by cell viability, microscopy, and Western blot assays, respectively. In addition, cell adhesion abilities were determined by counting the number of attached cells. The expression of fibronectin, collagen IV, matrix metalloproteinases 2 (MMP-2), and tissue inhibitors of matrix metalloproteinases 2 (TIMP-2) were analyzed using RT-PCR. MMP-2 activity was analyzed by zymography, whereas the activation of the MAPKs and Smad signaling were analyzed using Western blot assays and a reporter gene assay, respectively. RESULTS: Our results indicated that recombinant BMP6 induced ALP activity in a dose-dependent and time-course-dependent manner. Treatment with TGF-beta1 reduced both the cell proliferation and the expression of E-cadherin, induced a morphological transformation, decreased the expression and activity of MMP-2, and increased the expression levels of alpha-SMA, fibronectin, and TIMP-2 in HK-2 cells. All of these effects were inhibited when cells were treated with TGF-beta1 in combination with rhBMP6, whereas rhBMP6 alone demonstrated no such effect. Treatment with TGF-beta1, rhBMP6, or a combination of both had no effect on the expression of collagen IV. In addition, the administration of rhBMP6 prevented the enhanced adhesion behavior triggered by TGF-beta1. Furthermore, the addition of rhBMP6 abrogated the JNK and Smad2/3 signaling that was activated by TGF-beta1. CONCLUSION: BMP6 ameliorated the TGF-beta1-induced changes in HK-2 cells. The suppression of TGF-beta1-mediated JNK and Smad2/3 signaling activation were implicated in these effects.Acta Pharmacologica Sinica (2009) 30: 994-1000; doi: 10.1038/aps.2009.56; published online 22 June 2009.
AIM: The aim of the study was to investigate the potential role of BMP6 in TGF-beta1-mediated changes in HK-2 cells. METHODS:BMP6 was purified via heparin affinity and reverse phase liquid chromatography. The purity, specificity, and bioactivity of BMP6 were determined by SDS-PAGE, Western blot assays, and the induction of alkaline phosphatase (ALP) activity, respectively. Cell proliferation, morphology, and expression levels of alpha-SMA and E-cadherin were assessed by cell viability, microscopy, and Western blot assays, respectively. In addition, cell adhesion abilities were determined by counting the number of attached cells. The expression of fibronectin, collagen IV, matrix metalloproteinases 2 (MMP-2), and tissue inhibitors of matrix metalloproteinases 2 (TIMP-2) were analyzed using RT-PCR. MMP-2 activity was analyzed by zymography, whereas the activation of the MAPKs and Smad signaling were analyzed using Western blot assays and a reporter gene assay, respectively. RESULTS: Our results indicated that recombinant BMP6 induced ALP activity in a dose-dependent and time-course-dependent manner. Treatment with TGF-beta1 reduced both the cell proliferation and the expression of E-cadherin, induced a morphological transformation, decreased the expression and activity of MMP-2, and increased the expression levels of alpha-SMA, fibronectin, and TIMP-2 in HK-2 cells. All of these effects were inhibited when cells were treated with TGF-beta1 in combination with rhBMP6, whereas rhBMP6 alone demonstrated no such effect. Treatment with TGF-beta1, rhBMP6, or a combination of both had no effect on the expression of collagen IV. In addition, the administration of rhBMP6 prevented the enhanced adhesion behavior triggered by TGF-beta1. Furthermore, the addition of rhBMP6 abrogated the JNK and Smad2/3 signaling that was activated by TGF-beta1. CONCLUSION:BMP6 ameliorated the TGF-beta1-induced changes in HK-2 cells. The suppression of TGF-beta1-mediated JNK and Smad2/3 signaling activation were implicated in these effects.Acta Pharmacologica Sinica (2009) 30: 994-1000; doi: 10.1038/aps.2009.56; published online 22 June 2009.
Authors: Stefan Saremba; Joachim Nickel; Axel Seher; Alexander Kotzsch; Walter Sebald; Thomas D Mueller Journal: FEBS J Date: 2007-12-06 Impact factor: 5.542
Authors: K Lyons; J L Graycar; A Lee; S Hashmi; P B Lindquist; E Y Chen; B L Hogan; R Derynck Journal: Proc Natl Acad Sci U S A Date: 1989-06 Impact factor: 11.205
Authors: T K Sampath; J C Maliakal; P V Hauschka; W K Jones; H Sasak; R F Tucker; K H White; J E Coughlin; M M Tucker; R H Pang Journal: J Biol Chem Date: 1992-10-05 Impact factor: 5.157
Authors: Amélie Dendooven; Olivia van Oostrom; Dionne M van der Giezen; Jan Willem Leeuwis; Cristel Snijckers; Jaap A Joles; Elizabeth J Robertson; Marianne C Verhaar; Tri Q Nguyen; Roel Goldschmeding Journal: Am J Pathol Date: 2011-03 Impact factor: 4.307
Authors: Matheus Correa-Costa; Patricia Semedo; Ana Paula F S Monteiro; Reinaldo C Silva; Rafael L Pereira; Giselle M Gonçalves; Georgia Daniela Marcusso Marques; Marcos A Cenedeze; Ana C G Faleiros; Alexandre C Keller; Maria H M Shimizu; Antônio C Seguro; Marlene A Reis; Alvaro Pacheco-Silva; Niels O S Câmara Journal: PLoS One Date: 2010-12-13 Impact factor: 3.240
Authors: Denis Delić; Claudia Eisele; Ramona Schmid; Patrick Baum; Franziska Wiech; Martin Gerl; Heike Zimdahl; Steven S Pullen; Richard Urquhart Journal: PLoS One Date: 2016-03-01 Impact factor: 3.240